No data to show
OTCM
CTABF
Market cap0kUSD
Nov 19, Last price
0.00USD
Name
Canntab Therapeutics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
144.95%
Revenues
293k
Net income
-4m
L-16.53%
CFO
-3m
L-0.13%
Profile
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2015‑12 | |
| Income | |||||||
Revenues | 293 | ||||||
Cost of revenue | 3,256 | ||||||
Unusual Expense (Income) | |||||||
NOPBT | (2,963) | ||||||
NOPBT Margin | |||||||
Operating Taxes | 567 | ||||||
Tax Rate | |||||||
NOPAT | (3,529) | ||||||
Net income | (3,689) -16.53% | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 1,513 | ||||||
Long-term debt | 682 | ||||||
Deferred revenue | |||||||
Other long-term liabilities | 278 | ||||||
Net debt | 1,503 | ||||||
| Cash flow | |||||||
Cash from operating activities | (2,846) | ||||||
CAPEX | (88) | ||||||
Cash from investing activities | 151 | ||||||
Cash from financing activities | 1,895 | ||||||
FCF | (1,431) | ||||||
| Balance | |||||||
Cash | 691 | ||||||
Long term investments | |||||||
Excess cash | 676 | ||||||
Stockholders' equity | (3,256) | ||||||
Invested Capital | 4,257 | ||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 37,724 | ||||||
Price | 0.30 -70.79% | ||||||
Market cap | 11,129 -68.11% | ||||||
EV | 12,632 | ||||||
EBITDA | (2,328) | ||||||
EV/EBITDA | |||||||
Interest | 567 | ||||||
Interest/NOPBT | |||||||